The Role of Naltrexone-Bupropion in Obesity Management: Current State of Knowledge
DOI:
https://doi.org/10.12775/QS.2025.40.59421Keywords
Naltrexone-bupropion, Anti-obesity drugs, Weight loss medications, Obesity, OverweightAbstract
Introduction: Obesity is a chronic disease characterized by excessive fat accumulation, leading to significant health risks and numerous comorbidities. Its rising global prevalence demands effective management strategies1.
The aim of the study: This article examines the role of combined naltrexone-bupropion therapy in obesity treatment. It focuses on its indications, mechanism of action, efficacy in weight management, safety profile, and potential side effects.
Material and methods: A comprehensive literature review was performed using PubMed, Google Scholar, MedRxiv, and Scopus. The review included meta-analyses, randomized controlled trials, observational studies, and case reports assessing the pharmacotherapy of obesity with naltrexone-bupropion.
Summary of current knowledge: Pharmacotherapy is recommended alongside lifestyle modifications for obesity management. Naltrexone-bupropion works by targeting both hypothalamic appetite control and the mesolimbic reward system, leading to significant weight loss in clinical studies. However, its use is often accompanied by mild to moderate adverse effects, such as nausea and headaches.
Conclusions: Obesity requires a multifaceted treatment approach. Naltrexone-bupropion offers a promising adjunct to diet and exercise but long-term safety and individualized treatment strategies need further investigation.
References
1. Finucane MM, Stevens GA, Cowan M, et al. HHS Public Access participants. 2015;377(9765):557-567. http://doi.org/10.1016/S0140-6736(10)62037-5.National
2. Fruh SM. Obesity : Risk factors , complications , and strategies for sustainable long-term weight management. 2017;29:3-14. http://doi.org/10.1002/2327-6924.12510
3. Wiechert M, Holzapfel C. Nutrition Concepts for the Treatment of Obesity in Adults. 2022;2019.
4. Lega IC, Lipscombe LL. and Clinical Implications. (June 2019):33-52. http://doi.org/10.1210/endrev/bnz014
5. Scully T, Ettela A, Leroith D, Gallagher EJ. Obesity , Type 2 Diabetes , and Cancer Risk. 2021;10(February):1-20. http://doi.org/10.3389/fonc.2020.615375
6. Lin X, Li H. Obesity : Epidemiology , Pathophysiology , and Therapeutics. 2021;12(September):1-9. http://doi.org/10.3389/fendo.2021.706978
7. Neeland IJ, Ross R, Després J pierre, et al. Review Visceral and ectopic fat , atherosclerosis , and cardiometabolic disease : a position statement. :715-725. http://doi.org/10.1016/S2213-8587(19)30084-1
8. Zhou Y, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 ( Covid-19 ). 2021;(April 2020). http://doi.org/10.1002/dmrr.3377
9. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological Management of Obesity : An Endocrine Society Clinical Practice Guideline. 2015;100(February):342-362. http://doi.org/10.1210/jc.2014-3415
10. Bray GA, Ryan DH. Evidence-based weight loss interventions : Individualized treatment options to maximize patient outcomes. 2021;(September 2020):50-62. http://doi.org/10.1111/dom.14200
11. Rulkiewicz A, Pilchowska I, Lisik W, Pruszczyk P. Prevalence of Obesity and Severe Obesity among Professionally Active Adult Population in Poland and Its Strong Relationship with Cardiovascular Co-Morbidities-POL-O-CARIA 2016 – 2020 Study. Published online 2022.
12. Polish Society for the Treatment of Obesity; Clinical Recommendations for the Management of Patients with Obesity 2024. Published online 2024:1-116.
13. WHO EUROPEAN REGIONAL OBESITY REPORT 2022.; 2022.
14. Biertho L, Campbell-scherer D, Adamo K, et al. Obesity in adults : a clinical practice guideline. 2020;192(31). http://doi.org/10.1503/cmaj.191707
15. College of Family Physicians in Poland. Principles of treatment for overweight and obesity in family doctor practice. Published online 2014.
16. Sundbom M, Järvholm K, Sjögren L, Lagerros YT, Nowicka P. Obesity treatment in adolescents and adults in the era of personalized medicine. Published online 2024:139-155. http://doi.org/10.1111/joim.13816
17. Olszanecka-glinianowicz M, Mazur A, Chudek J, et al. Obesity in Adults : Position Statement of Polish Association for the Study on Obesity , Polish Association of Endocrinology , Polish Association of Cardiodiabetology , Polish Psychiatric Association , Section of Metabolic and Bariatric Surgery of the Association of Polish Surgeons , and the College of Family Physicians in Poland. Published online 2023.
18. Sciences P, Branch DE, Service DI. HHS Public Access. 2018;20(3):270-279.
19. Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Advances in Therapy. 2021;38(6):2821-2839. http://doi.org/10.1007/s12325-021-01710-0
20. Zhao G jack WJ, Tomasi D, Shokri E, et al. Effect of combined naltrexone and bupropion therapy on the brain ’ s functional connectivity. International Journal of Obesity. Published online 2018:1890-1899. http://doi.org/10.1038/s41366-018-0040-2
21. Nowak M. Tirzepatide — a dual GIP / GLP-1 receptor agonist — a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes. Published online 2022. http://doi.org/10.5603/EP
22. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes e state-of-the-art. Molecular Metabolism. 2021;46(October 2020):101102. http://doi.org/10.1016/j.molmet.2020.101102
23. Filipiak KJ, Narkiewicz K, Windak A, Czupryniak L. Opinion of the Expert Team on the use of Mysimba & (bupropionus hydrochloride, naltrexone hydrochloride) in the supportive treatment of overweight obese patients ( BMI ≥ 27 kg / m 2 ) with comorbidities. 2016;(5):333-346.
24. Kulak-bejda A, Bejda G, Waszkiewicz N. Systematic review / Meta-analysis Safety and efficacy of naltrexone for weight loss in adult patients – a systematic review. Published online 2021.
25. Aaseth J, Ellefsen S, Alehagen U, Sundf TM, Alexander J. Biomedicine & Pharmacotherapy Diets and drugs for weight loss and health in obesity – An update. 2021;140(May):0-2. http://doi.org/10.1016/j.biopha.2021.111789
26. Apovian CM, Aronne L, Rubino D, et al. Obesity A Randomized , Phase 3 Trial of Naltrexone SR / Bupropion SR on Weight and Obesity- related Risk Factors ( COR-II ). 2013;21(5):935-943. http://doi.org/10.1002/oby.20309
27. Woch B, Bereza D, Sokołowska K, et al. Pharmacological treatment of obesity : an overview of different groups of anti-obesity drugs available in Poland Abstract Introduction and Objective : Obesity , as one of the diseases of civilization , has become a significant problem in our time . Althou. Published online 2024:48-59.
28. Greenway FL, Fujioka K, Plodkowski RA, et al. Eff ect of naltrexone plus bupropion on weight loss in overweight and obese adults ( COR-I ): a multicentre , randomised , double-blind , placebo-controlled , phase 3 trial. The Lancet. 2010;376(9741):595-605. http://doi.org/10.1016/S0140-6736(10)60888-4
29. Wadden TA, Foreyt JP, Foster GD, et al. HHS Public Access. 2015;19(1):110-120. http://doi.org/10.1038/oby.2010.147.Weight
30. Verpeut JL, Bello NT. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opinion on Drug Safety. 2014;13(6):831-841. http://doi.org/10.1517/14740338.2014.909405
31. Naltrexone-Bupropion. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Published online 5 June 2020. Accessed February 2, 2025. https://www.ncbi.nlm.nih.gov/books/NBK559444/
32. Grilo CM, Lydecker JA, Jastreboff AM, Pittman B, Mckee SA. Naltrexone/Bupropion for Binge-Eating Disorder: A Randomized Double-Blind Placebo-Controlled Trial HHS Public Access. http://doi.org/10.1002/oby.23898
33. Dahlberg S, Chang ET, Weiss SR, Dopart P, Gould E, Ritchey ME. Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review. Diabetes, Metabolic Syndrome and Obesity. 2022;15(September):3049-3067. http://doi.org/10.2147/DMSO.S381652
34. Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ. Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. British Journal of Clinical Pharmacology. 2020;86(4):646-667. http://doi.org/10.1111/bcp.14210
35. Basiak M, Hachuła M, Kosowski M, Ziela K. The Impact of Various Methods of Obesity Treatment on the Quality of Life and Mental Health — A Narrative Review. Published online 2023.
36. Place C, Wharf C, Telephone UK, Agency EM. Mysimba. 2015;44(0):4-6.
37. Son JW, Kim S. Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. Published online 2020:802-818.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Martyna Grabowska, Karolina Grabowska, Jagoda Kubicka, Aleksandra Wiśniewska, Dominik Balik, Anna Kwaśniewska, Karolina Kaszyńska, Jakub Dąbek, Wiktoria Kosucka, Joanna Lara
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 142
Number of citations: 0
